Complete pain relief: Potential problems and diagnostic solutions

Nature Clinical Practice Neurology

Volumn 3, Issue 12, 2007, Pages 648-649

  Mannes, Andrew J ^a   Iadarola, Michael J ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RESINIFERATOXIN;

ANALGESIA; ANALGESIC ACTIVITY; ARTHRITIS; ARTICLE; BACKACHE; CANCER PAIN; CHRONIC PAIN; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE DURATION; DOPING; DRUG CHOICE; DRUG TARGETING; FIBROMYALGIA; HEALTH CARE COST; HUMAN; MIGRAINE; NONHUMAN; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

ANALGESIA; HUMANS; PAIN;

EID: 36949037140     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0660     Document Type: Article

References (10)

1. Gureje O et al. (1998) Persistent pain and well-being: A World Health Organization study in primary care. JAMA 280: 147-151
2. Frymoyer JW and Cats-Baril WL (1991) An overview of the incidences and costs of low back pain. Orthop Clin North Am 22: 263-271
3. Ekman M et al. (2005) The economic cost of low back pain in Sweden in 2001. Acta Orthop 76: 275-284
4. Brown DC et al. (2005) Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology 103: 1052-1059
5. Benoliel R et al. (1999) Actions of intrathecal diphtheria toxin-substance P fusion protein on models of persistent pain. Pain 79: 243-253
6. Mantyh PW et al. (1997) Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science 278: 275-279
7. Vulchanova L et al. (2001) Cytotoxic targeting of isolectin IB4-binding sensory neurons. Neuroscience 108: 143-155
8. Cox JJ et al. (2006) An SCN9A channelopathy causes congenital inability to experience pain. Nature 444: 894-898
9. Nagasako EM et al. (2003) Congenital insensitivity to pain: An update. Pain 101: 213-219
10. Metzl JD (2005) Anabolic steroids and the pediatric community. Pediatrics 116: 1542